Literature DB >> 34921099

Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity.

Joseph L Jilek1, Kayla L Frost1, Solène Marie1, Cassandra M Myers1, Michael Goedken1, Stephen H Wright1, Nathan J Cherrington2.   

Abstract

Ochratoxin A (OTA) is an abundant mycotoxin, yet the toxicological impact of its disposition is not well studied. OTA is an organic anion transporter (OAT) substrate primarily excreted in urine despite a long half-life and extensive protein binding. Altered renal transporter expression during disease, including nonalcoholic steatohepatitis (NASH), may influence response to OTA exposure, but the impact of NASH on OTA toxicokinetics, tissue distribution, and associated nephrotoxicity is unknown. By inducing NASH in fast food-dieted/thioacetamide-exposed mice, we evaluated the effect of NASH on a bolus OTA exposure (12.5 mg/kg by mouth) after 3 days. NASH mice presented with less gross toxicity (44% less body weight loss), and kidney and liver weights of NASH mice were 11% and 24% higher, respectively, than healthy mice. Organ and body weight changes coincided with reduced renal proximal tubule cells vacuolation, degeneration, and necrosis, though no OTA-induced hepatic lesions were found. OTA systemic exposure in NASH mice increased modestly from 5.65 ± 1.10 to 7.95 ± 0.61 mg*h/ml per kg BW, and renal excretion increased robustly from 5.55% ± 0.37% to 13.11% ± 3.10%, relative to healthy mice. Total urinary excretion of OTA increased from 24.41 ± 1.74 to 40.07 ± 9.19 µg in NASH mice, and kidney-bound OTA decreased by ∼30%. Renal OAT isoform expression (OAT1-5) in NASH mice decreased by ∼50% with reduced OTA uptake by proximal convoluted cells. These data suggest that NASH-induced OAT transporter reductions attenuate renal secretion and reabsorption of OTA, increasing OTA urinary excretion and reducing renal exposure, thereby reducing nephrotoxicity in NASH. SIGNIFICANCE STATEMENT: These data suggest a disease-mediated transporter mechanism of altered tissue-specific toxicity after mycotoxin exposure, despite minimal systemic changes to ochratoxin A (OTA) concentrations. Further studies are warranted to evaluate the clinical relevance of this functional model and the potential effect of human nonalcoholic steatohepatitis on OTA and other organic anion substrate toxicity.
Copyright © 2022 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34921099      PMCID: PMC9513848          DOI: 10.1124/dmd.121.000451

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.579


  50 in total

Review 1.  Mechanisms and clinical implications of renal drug excretion.

Authors:  R Masereeuw; F G Russel
Journal:  Drug Metab Rev       Date:  2001 Aug-Nov       Impact factor: 4.518

2.  Nephrotoxicity of dietary ochratoxin A in broiler chickens.

Authors:  W E Huff; R D Wyatt; P B Hamilton
Journal:  Appl Microbiol       Date:  1975-07

Review 3.  Transporters as a determinant of drug clearance and tissue distribution.

Authors:  Yoshihisa Shitara; Toshiharu Horie; Yuichi Sugiyama
Journal:  Eur J Pharm Sci       Date:  2006-02-20       Impact factor: 4.384

4.  Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.

Authors:  Bhagwat Prasad; Raymond Evers; Anshul Gupta; Cornelis E C A Hop; Laurent Salphati; Suneet Shukla; Suresh V Ambudkar; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2013-10-11       Impact factor: 3.922

Review 5.  Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Nathan J Cherrington
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-07-03       Impact factor: 4.481

Review 6.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

Review 7.  Renal organic anion transporters in drug-drug interactions and diseases.

Authors:  Xiaokui Huo; Kexin Liu
Journal:  Eur J Pharm Sci       Date:  2017-11-08       Impact factor: 4.384

8.  Gender differences in expression of organic cation transporter OCT2 in rat kidney.

Authors:  Y Urakami; N Nakamura; K Takahashi; M Okuda; H Saito; Y Hashimoto; K Inui
Journal:  FEBS Lett       Date:  1999-11-19       Impact factor: 4.124

9.  Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Authors:  Mark J Canet; Rhiannon N Hardwick; April D Lake; Anika L Dzierlenga; John D Clarke; Michael J Goedken; Nathan J Cherrington
Journal:  Drug Metab Dispos       Date:  2014-12-08       Impact factor: 3.922

Review 10.  Ochratoxin A and human health risk: a review of the evidence.

Authors:  Travis R Bui-Klimke; Felicia Wu
Journal:  Crit Rev Food Sci Nutr       Date:  2015       Impact factor: 11.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.